Update on polymyalgia rheumatica;Pseudopolyarthrites rhizoméliques: Mise au point

Revue de Medecine Interne

Volumn 23, Issue 6, 2002, Pages 518-532

  Laborie, Y ^a   Berthelot, J M ^a  

^a HÔTEL DIEU   (France)

Author keywords

Diagnosis; Erythrocyte sedimentation rate; Polymyalgia rheumatica; Treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTILIPEMIC AGENT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DAPSONE; DEFLAZACORT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ENALAPRIL; GAMMA INTERFERON; HISTAMINE H2 RECEPTOR ANTAGONIST; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MINOXIDIL; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ARTHRITIS; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PARANEOPLASTIC SYNDROME; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; RHEUMATIC DISEASE; RHEUMATIC POLYMYALGIA; SYNOVITIS; TEMPORAL ARTERITIS; URINARY TRACT INFECTION;

EID: 0036077483     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(02)00607-0     Document Type: Short Survey

References (86)

1. The epidemiology of polymyalgia rheumatica and giant cell arteritis: A community based study in the UK
2. Polymyalgia rheumatica a 10 years epidemiologic and clinical study
3. Epidemiology of polymyalgia rheumatica in Olmsted County, 1970-1991
4. Prévalence et fréquences respectives de la maladie de Horton et de la pseudopolyarthrite rhizomélique. Étude épidémiologique dans le département de Loire-Atlantique avec utilisation d'un réseau de recherche de médecine générale (RESOMED 44
5. Epidemiology of polamyalgia rheumatica
6. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy
7. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, South Norway: A prospective study 1987-94
8. Polymyalgia rheumatica
9. Giant cell arteritis in polymyalgia rheumatica
10. Treatment of polymyalgia rheumatica
11. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis
12. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: Clinical and laboratory manifestations at onset of disease and at time of diagnosis
13. Rheumatologists'performance in daily practice
14. Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis
15. Polymyalgia rheumatica
16. Distal musculoskelatal manifestations in polymyalgia rheumatica. A prospective follow-up study
17. Diagnostic dilemmas in polymyalgia rheumatica
18. An evaluation of criteria for polymyalgia rheumatica
19. Prognosis and management of polymyalgia rheumatica
20. The accuracy of diagnosis in polymyalgia rheumatica (PMR): Results from a PMR referral clinic
21. Prognosis in the anesthitic rheumatoid syndrome
22. Seronegative polyarthritis and giant cell arteritis
23. Acute febrile polyarthritis disclosing Horton's disease
24. Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis
25. Outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis
26. RS3PE syndrome and polymyalgia rheumatica: Distinghishing features
27. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome: A prospective follow-up and magnetic resonance imaging study
28. The ESR in the diagnosis and management of polymyalgia rheumatica/giant cell arteritis syndrome
29. Polymyalgia rheumatica with normal erythrocyte sedimentation rate: Clinical aspects
30. ESR and C-reactive proteine in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow-up
31. ESR in polymyalgia rheumatica and giant cell arteritis
32. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis
33. Raised ESR in polymyalgia rheumatica no longer a sine qua non?
34. Erythrocyte sedimentation rate (ESR) at presentation is a pronostic indicator for duration of treatment in polymyalgia rheumatica
35. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica
36. Hepatocellular disease in the giant cell arteritis/polymyalgia rheumatica syndrome
37. Hypothyroïdie transitoire à la phase initiale de la pseudopolyarthrite rhizomélique
38. Non Hodgkin's lymphoma and subsequent acute lymphoblastic leukemia in a patient with polymyalgia rheumatica
39. Manifestations articulaires et myélodysplasies, à propos de 3 cas se présentant comme des pseudopolyarthrites rhzoméliques
40. Cancer in association with polymyalgia rheumatica and temporal arteritis
41. Cytidine deaminase may be a useful marker in differentiating elderly onset rheumatoid arthritis from polymyalgia rheumatica/giant cell arteritis
42. Polymyalgia rheumatica and seronegative rheumatoid arthritis may be the same entity
43. Actualités des rhumatismes inflammatoires du sujet âgé
44. Musculoskeletal manifestations of bacterial endocarditis
45. Ultrasonographic evidence of synovitis in axial joints in patients with polymyalgia rheumatica
46. Polymyalgia rheumatica: An arthroscopic study of the shoulder joint
47. Leucocyte infiltration in synovial tissue from the shoulders of patients with polymyalgia rheumatica: Quantification analysis and influence of corticosteroid treatment
48. Proximal bursitis in active polymyalgia rheumatica
49. Magnetic resonance imaging in the diagnosis of PMR
50. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography
51. Relation entre pseudopolyarthrite rhizomélique et myopathies mitochondriales: 24 observations
52. P31 magnetic resonance spectroscopie demonstrate inaltered muscle energy utilisation in polymyalgia rheumatica
53. Polymyalgia rheumatica: Evidence for a hypothalamic-pituitary-adrenal axis driven disease
54. Disease patterns and tissue cytokine profiles in giant cell arteritis
55. Platelet derived growth factor, intimal hyperplasia and ischemic complications in giant cell arteritis
56. Vascular endothelial growth factor production in polymyalgia rheumatica
57. HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: Correlation with disease severity
58. DRB1 alleles in polymyalgia rheumatica and rheumatoid arthritis in southern France
59. HLADRB1 alleles in polymyalgia rheumatica, giant cell arteritis and rheumatoid arthritis
60. Étude du polymorphisme HLA-DRB1 au cours de la pseudopolyarthrite rhizomélique et de la maladie de Horton
61. Reduced CD8+ lymphocytes subset distinguished patients with polmyalgia rheumatica and temporal arteritis from patients with other disease
62. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis
63. Giant cell arteritis and cardiovascular risk factors: A multicenter, prospective case control study
64. Prévalence des anticorps antiphospholipides dans la maladie de Horton et dans la pseudopolyarthrite rhizomélique
65. Synchronous variations of incidence of temporal arteritis and polymyalgia rheumatica in different regions of Danemark; association with epidemics of Mycoplasma pneumoniae infections
66. Maladie de Horton, pseudopolyarthrite rhizomélique, et facteurs de risque cardio-vasculaires: Une étude cas-témoins prospective et multicentrique
67. Elevated soluble intercellular molecule 1 in the serum of patients with polymyalgia rheumatica: Influence of steroid treatment
68. Correlation of IL-6 production and desease activity in polymyamlgia rheumatica and giant cell arteritis
69. Treatment of polymyalgia rheumatica and giant cell arteritis. II: Relation between steroid dose and steroid associated side effects
70. Polymyalgia rheumatica and temporal arteritis: A retrospective analysis of prognosis features and different corticosteroid regimens
71. Longterm therapy in polymyalgia rheumatica: Effect of coexistent temporal arteritis
72. The deleterious effects of low dose corticosteroids on bone density in patients with PMR
73. Treatment of polymyalgia rheumatica during the first 6 months. A comparaison of two steroid regimens
74. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of PMR
75. Longterm outcome of anti-inflammatory therapy in a population based study of polymyalgia rheumatica. 1970-1991
76. Steroid sparing activity of tenidap in patients with polymyalgia rheumatica: A multicenter double blind randomized placebo controlled study
77. Adverse outcomes of anti-inflammatory therapy among patients with PMR
78. Immunosuppressive agents in Horton's disease
79. The use of methotrexate in polymyalgia rheumatica
80. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
81. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, doubleblind, placebo-controlled trial
82. Azathioprine in giant cell arteritis/polymyalgia rheumatica: A double blind study
83. Ciclosporine, a new adjuvant therapy for giant cell arteritis
84. Traitement de la maladie de Horton. Intérêt des antipaludéens de synthèse. À propos d'une série rétrospective de 36 patients
85. Sulfamethoxazole/ trimethoprim, therapy for polymyalgia rheumatica. Report of 5 cases